Sarah Hobdey
PhD
Research Assistant Professor
BMS
Dr. Hobdey earned her B.S. in Microbiology from Idaho State University, where she also competed on the Women’s Soccer team. She went on to obtain her Ph.D. in Biochemistry and Molecular Biology from Colorado State University and completed postdoctoral training at the National Renewable Energy Laboratory before returning home to Idaho. Dr. Hobdey's research is focused on the development of novel therapies and diagnostics for life-threatening necrotizing soft tissue infections (NSTIs). In progress towards that goal, she and her team have developed three patent-pending fully human monoclonal antibodies capable of neutralizing streptolysin O, a key toxin produced by Group A Streptococcus. In addition to her role at Idaho State University, Dr. Hobdey is an Associate Research Scientist at the Boise VA Medical Center, where she maintains an active research laboratory.
Select Papers
https://www.ncbi.nlm.nih.gov/myncbi/sarah.hobdey.1/bibliography/public/
Past Trainee's
Postdoctoral Fellows
Graduate Students
Undergraduate Students
Other Past and Current Team Members
Active Grants and/or Previous Grants
Idaho CTRD (Hobdey, Project Lead), NIH-NIGMS P20GM155959, 9/1/26-8/31/28, Advancing a First-in-Class Antitoxin Monoclonal Antibody Therapy for Severe Group A Streptococcal Infections: Foundational Studies Toward IND Readiness
Idaho INBRE DRP (Hobdey, Project Lead), NIH NIGMS P20GM103408, 5/2024-8/2026, Generation of fully human recombinant antitoxin antibodies for the treatment of necrotizing infections
Paratek Pharmaceuticals (Hobdey, PI), Investigating the Effects of Omadacycline on the Microbiome in a Murine Model of Secondary
MRSA Pneumonia
Hiring Graduate Students/ Post-Docs/ Lab Assistants
Not hiring at this time.